IGI Logo

We recently met Venkat Jasti, the promoter of Suven Life Sciences. The company highlighted continued progress across its CNS pipeline. SUVN-502 (Masupirdine) is the company’s lead molecule, with ~95% of patients enrolled in the global Phase 3 trial for agitation in Alzheimer’s dementia, with full enrolment expected by Sep-26, last-patient-last-visit in 1QCY27, and data readout in 2QCY27. The management expressed confidence in the drug’s safety profile, noting that the molecule had undergone a 560-patient trial without any product-related side effects and that an interim analysis on the first 50% of enrolled patients indicated no requirement for a protocol amendment; this reinforces management's view that Masupirdine will not carry any label requirements such as a black box warning or REMS. The company also noted that no new drug for Alzheimer’s has been approved since 2001 and 70- 80% of agitation patients in Alzheimer’s dementia remain untreated; hence, fasttrack designation can be pursued to potentially enable direct registration. SUVNG3031 (Samelisant) began its global Phase 3 for excessive daytime sleepiness (EDS) in narcolepsy in Apr-26, targeting 240 patients, with enrolment expected to be completed by Dec-27/Mar-28. Given that the mechanism of action is already proven and Samelisant’s safety profile is better vs existing therapies (efficacy is comparable), the management expects it to become a best-in-class molecule without any safety labels. SUVN-911 (Ropanicant) has completed its US Phase 2B study, with a positive data readout, and the Phase 3 study is expected to begin in 2HCY27. Per the company, the drug has out-licensing potential given low depression remission rates (30-35%) in the current regimen and the molecule's tolerability/ease of use, with a follow-on cognition trial also planned.

Licensing-led strategy to fund late-stage clinical development

The management highlighted estimated Phase 3 trial costs of ~$45mn for Samelisant and ~$70mn for Ropanicant. The company reiterated that Suven's core strength lies in discovery rather than commercialization, making licensing and partnerships (historically ~$100-150mn upfront, plus milestones and royalties in this segment) central to funding future trials, supplemented by potential PE capital.

Risk profile of CNS assets limits early licensing opportunities

The management indicated that out-licensing is likely only post-Phase 3, given the risk profile of CNS assets. Companies are typically risk-averse in licensing early-stage assets, given significantly high attrition rates owing to reliance on qualitative rather than quantitative efficacy endpoints. Other near-term risks include the possibility that the FDA may still require additional Masupirdine studies despite the 560-patient dataset and its safety profile. Future trial funding will be an outcome of possible out-licensing of late-stage assets or, if that does not materialize, a fund raise or promoter infusion toward end-CY26.

KTAs from the management meeting

1) Masupirdine will have a novel mechanism with a large addressable unmet need. Its primary competitor, Rexulti, posted $2bn in global sales in CY25, and no head-to-head trial against Rexulti is required.

2) The company expects to launch Masupirdine in CY28. Patent expiry of Rexulti (CY33) will not have an impact on the sales potential of Masupirdine.

3) Ropanicant can be a larger opportunity than Masupirdine, with a possibility of partnering with big pharma.

4) For Usmarapride, the USFDA has accepted that cognition in depression can be an indication, and the company will start Phase 2 trials by end-CY26.

5) Auvelity was recently approved for the treatment of agitation associated with dementia due to Alzheimer’s disease, positioning it as a competitor to Masupirdine. The management, however, believes that Masupirdine has a better safety profile.

6) Samelisant has a better safety profile vs Wakix (Pitolisant), which is on track to be a blockbuster drug, while Xywav poses challenges including middle-of-the-night dosing and a black box warning.

7) The company’s Singapore subsidiary will enable partnerships with big pharma, while IP will remain in India.

8) Suven conducts 6-month rat/9-month dog toxicology studies for its drugs well ahead of schedule, ie, before Phase 2, so that safety is firmly established even before proof of concept in patients is achieved.

9) The company’s products are all immediate-release formulations and can be prescribed by primary care professionals.

For More  Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354